Novartis AG (LON:0K9E)

London flag London · Delayed Price · Currency is GBP · Price in USD
113.95
-4.13 (-3.50%)
At close: Aug 6, 2025
-3.50%
Market Cap166.24B
Revenue (ttm)40.28B
Net Income (ttm)9.97B
Shares Outn/a
EPS (ttm)5.00
PE Ratio16.68
Forward PE13.50
Dividend2.61 (2.29%)
Ex-Dividend DateMar 12, 2025
Volume867
Average Volume29,377
Open119.00
Previous Close118.08
Day's Range113.88 - 119.00
52-Week Range96.11 - 128.50
Betan/a
RSI45.87
Earnings DateJul 17, 2025

About Novartis AG

Novartis AG engages in the research, development, manufacture, distribution, marketing, and sale of pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Re... [Read more]

Industry Pharmaceutical Preparations
Founded 1996
Employees 75,883
Stock Exchange London Stock Exchange
Ticker Symbol 0K9E
Full Company Profile

Financial Performance

In 2024, Novartis AG's revenue was $51.72 billion, an increase of 10.85% compared to the previous year's $46.66 billion. Earnings were $11.94 billion, a decrease of -19.59%.

Financial numbers in USD Financial Statements

News

There is no news available yet.